Point72 Asset Management
ADVM

Point72 Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Point72 Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,840
Closed -$1.56M – 950
2021
Q1 		$1.56M Buy
+15,840
New +$1.9M 0.01% 760

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Point72 Asset Management's ADVM Position: Q2 2019 in Review

Point72 Asset Management sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 40,000 shares — an estimated $2.1M sold.

Point72 Asset Management first reported a position in ADVM in Q4 2018 and held it in 2 quarters. The position peaked at $2.1M in Q1 2019. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

  • Point72 Asset Management reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
  • Point72 Asset Management sold 40,000 Adverum Biotechnologies shares in Q2 2019, an estimated $2.1M.
  • Point72 Asset Management first reported a position in Adverum Biotechnologies in Q4 2018 and held it in 2 quarters.
  • Point72 Asset Management's Adverum Biotechnologies position peaked at $2.1M in Q1 2019.
  • 94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on Point72 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.